Maureen J.B. Aarts

6.6k total citations · 1 hit paper
99 papers, 2.0k citations indexed

About

Maureen J.B. Aarts is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Maureen J.B. Aarts has authored 99 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Oncology, 46 papers in Molecular Biology and 25 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Maureen J.B. Aarts's work include Cancer Immunotherapy and Biomarkers (26 papers), Cutaneous Melanoma Detection and Management (25 papers) and Melanoma and MAPK Pathways (23 papers). Maureen J.B. Aarts is often cited by papers focused on Cancer Immunotherapy and Biomarkers (26 papers), Cutaneous Melanoma Detection and Management (25 papers) and Melanoma and MAPK Pathways (23 papers). Maureen J.B. Aarts collaborates with scholars based in Netherlands, United States and Germany. Maureen J.B. Aarts's co-authors include Manon van Engeland, F P J Vrouenraets, C. Dehing, Frans J.M.E. Roumen, Eline S.A. van den Akker, Vivianne C. G. Tjan‐Heijnen, John B.A.G. Haanen, Sophie C. Joosten, Veerle Melotte and Franchette W.P.J. van den Berkmortel and has published in prestigious journals such as Nature Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Maureen J.B. Aarts

89 papers receiving 2.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib

2018 306 citations Axel Bex, Maureen J.B. Aarts et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Maureen J.B. Aarts	784	770	768	393	314	99	2.0k
Audrey Mauguen	785 1.0×	406 0.5×	509 0.7×	321 0.8×	185 0.6×	111	2.1k
Joseph Kerger	1.5k 1.9×	382 0.5×	606 0.8×	266 0.7×	799 2.5×	69	2.4k
Thomas L. Jang	579 0.7×	979 1.3×	1.4k 1.8×	221 0.6×	637 2.0×	120	2.5k
Anne Floquet	1.3k 1.7×	442 0.6×	758 1.0×	521 1.3×	665 2.1×	170	3.3k
G. Pentheroudakis	1.3k 1.6×	500 0.6×	411 0.5×	384 1.0×	331 1.1×	33	2.2k
Sadhana Kannan	512 0.7×	694 0.9×	780 1.0×	384 1.0×	509 1.6×	145	2.6k
Franck Bladou	553 0.7×	469 0.6×	1.2k 1.6×	205 0.5×	600 1.9×	112	2.3k
Ubirajara Ferreira	345 0.4×	399 0.5×	1.8k 2.3×	447 1.1×	602 1.9×	132	2.6k
Christianne Lok	625 0.8×	276 0.4×	219 0.3×	158 0.4×	374 1.2×	90	1.7k
Dirk Klingbiel	2.5k 3.2×	753 1.0×	1.0k 1.3×	641 1.6×	552 1.8×	86	3.8k

Countries citing papers authored by Maureen J.B. Aarts

Since Specialization

Citations

This map shows the geographic impact of Maureen J.B. Aarts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maureen J.B. Aarts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maureen J.B. Aarts more than expected).

Fields of papers citing papers by Maureen J.B. Aarts

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maureen J.B. Aarts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maureen J.B. Aarts. The network helps show where Maureen J.B. Aarts may publish in the future.

Co-authorship network of co-authors of Maureen J.B. Aarts

This figure shows the co-authorship network connecting the top 25 collaborators of Maureen J.B. Aarts. A scholar is included among the top collaborators of Maureen J.B. Aarts based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maureen J.B. Aarts. Maureen J.B. Aarts is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Robbrecht, Debbie, John W.M. Martens, Maureen J.B. Aarts, et al.. (2025). Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer—A Patient Cohort Analysis. European Urology Oncology. 9(1). 7–11. 1 indexed citations

Zondervan, Patricia, Rob Kessels, Johannes Berkhof, et al.. (2024). PrimerX: A Bayesian Multistage Cohort Embedded Randomised Trial to Evaluate the Role of Deferred Local Therapy of the Primary Tumour in Combination with Immune Checkpoint Inhibitor–based First-line Therapy in Metastatic Renal Cell Carcinoma Patients. European Urology Open Science. 70. 28–35. 1 indexed citations

Aarts, Maureen J.B., Franchette van den Berkmortel, Christian U. Blank, et al.. (2024). Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: Propensity score–matched recurrence-free, distant metastasis-free, and overall survival analysis.. Journal of Clinical Oncology. 42(16_suppl). 9573–9573. 1 indexed citations

Joode, Karlijn de, John B.A.G. Haanen, Karijn P.M. Suijkerbuijk, et al.. (2024). Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma. Scientific Reports. 14(1). 11244–11244. 3 indexed citations

Geurts, Birgit S., Laurien J. Zeverijn, Vincent van der Noort, et al.. (2024). Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol. The Lancet Regional Health - Europe. 39. 100875–100875. 16 indexed citations

Poll‐Franse, Lonneke V. van de, Renaud Tissier, Anne Rogiers, et al.. (2023). Health-state utilities in long-term advanced melanoma survivors comparable with the general population. Quality of Life Research. 32(9). 2517–2525. 3 indexed citations

Hiel, Bernies van der, Else A. Aalbersberg, Alfons J.M. van den Eertwegh, et al.. (2023). The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III–IV BRAF-Mutated Melanoma Patients Treated With Targeted Therapy—What Can Be Learned From Progression?. Clinical Nuclear Medicine. 49(2). 138–145. 1 indexed citations

Eertwegh, Alfons J.M. van den, John B.A.G. Haanen, Rozemarijn S. van Rijn, et al.. (2023). Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies. European Journal of Cancer. 186. 27–37. 2 indexed citations

Wouters, Michel W.J.M., Doranne L. Hilarius, Liesbeth C. de Wreede, et al.. (2022). End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study. JCO Oncology Practice. 18(10). e1611–e1620. 3 indexed citations

10.

Robbrecht, Debbie, Ronald de Wit, Vanja de Weerd, et al.. (2022). Genome‐wide aneuploidy detected by mFast‐SeqS in circulating cell‐free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer. Molecular Oncology. 16(10). 2086–2097. 14 indexed citations

11.

Powles, Thomas, Srikala S. Sridhar, Yohann Loriot, et al.. (2021). Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. Nature Medicine. 27(12). 2200–2211. 74 indexed citations

12.

Wouters, Michel W.J.M., Doranne L. Hilarius, John B.A.G. Haanen, et al.. (2021). First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis. British Journal of Cancer. 124(7). 1222–1230. 15 indexed citations

13.

Franken, M, B Leeneman, Maureen J.B. Aarts, et al.. (2021). Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs. ESMO Open. 6(6). 100320–100320. 21 indexed citations

14.

Zeijl, Michiel C.T. van, Alfons J.M. van den Eertwegh, Michel W.J.M. Wouters, et al.. (2021). Discontinuation of anti‐PD‐1 monotherapy in advanced melanoma—Outcomes of daily clinical practice. International Journal of Cancer. 150(2). 317–326. 18 indexed citations

15.

Verver, D., Dirk J. Grünhagen, Alexander C. J. van Akkooi, et al.. (2021). Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy. Cancer Immunology Immunotherapy. 70(11). 3123–3135. 7 indexed citations

16.

Wit, Ronald de, Jourik A. Gietema, Gerard Groenewegen, et al.. (2020). Incidence of metachronous contralateral testicular germ cell tumour and association with chemotherapy. European Urology Open Science. 19. e405–e406.

17.

Verheijden, Rik J., Anne M. May, Christian U. Blank, et al.. (2020). Lower risk of severe checkpoint inhibitor toxicity in more advanced disease. ESMO Open. 5(6). e000945–e000945. 10 indexed citations

18.

Leeneman, B, Carin A. Uyl‐de Groot, Maureen J.B. Aarts, et al.. (2020). Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. Cancers. 12(4). 1003–1003. 12 indexed citations

19.

Tullemans, Bibian M. E., Magdolna Nagy, Siamack Sabrkhany, et al.. (2018). Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients. Frontiers in Cardiovascular Medicine. 5. 142–142. 18 indexed citations

20.

Vlodrop, Iris J.H. van, Sophie C. Joosten, Tim De Meyer, et al.. (2016). A Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients. Clinical Cancer Research. 23(8). 2006–2018. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact